HCPCS Level II code J3241 denotes a 10 mg unit of teprotumumab-trbw, an intravenously administered monoclonal antibody used in specialty infusion settings. As a high-cost biologic, accurate coding and consistent payer recognition are important for reimbursement, clinical documentation, and care coordination. This code matters nationally because it applies to specialty infusion providers, hospital outpatient departments, and payers managing access to complex biologic therapies.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical purpose and service setting, typical billing considerations, and where to expect payer coverage variations. The publication outlines benchmarks and policy context relevant to billing J3241, highlights common modifiers used in practice (input list), and summarizes implications for service line reporting and revenue cycle workflows.

This summary is intended to orient clinicians, billing professionals, and policy analysts to the primary clinical description, typical sites of service, and the payer landscape for HCPCS Level II code J3241. Data not available in the input is noted where applicable.